Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, Share & Trends Analysis Report By Product | Forecast to 2029
Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Will The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Valuation Change Between Now And 2029?
In recent years, there has been a significant expansion in the market size of therapeutics for Duchenne muscular dystrophy (DMD). The potential growth from $11.95 billion in 2024 to $16.38 billion in 2025, at a compound annual growth rate (CAGR) of 37.0%, is anticipated. This historical growth trajectory can be linked to factors such as the rising incidence of Duchenne muscular dystrophy, the augmentation of awareness about its treatment, elevated healthcare expenditures, and government programs.
In the coming years, the market size for Duchenne Muscular Dystrophy (DMD) therapeutics is projected to experience significant growth, hitting $47.74 billion by 2029, representing a Compound Annual Growth Rate (CAGR) of 30.7%. The upward trend during this period will be influenced by increased investments in DMD treatments, the utilization of combined therapies, the emergence of biomarkers, and the rising frequency of Duchenne Muscular Dystrophy screening programs. The forecast period will also see cutting-edge treatments for Duchenne Muscular Dystrophy, advancements in targeted therapies, introduction of brand-new medications and therapies, pioneering disease-altering therapies, and dynamic drug developments.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12916&type=smp
What Market Forces Are Contributing To The Growth Of The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
The increasing volume of clinical trials is anticipated to stimulate the expansion of the Duchenne muscular dystrophy (DMD) therapeutics market. Clinical trials are human-based research studies designed to assess the safety, effectiveness and potential advantages of novel medical therapies, treatments, or medicines. The escalation in clinical trials aimed at Duchenne muscular dystrophy intervention indicates ongoing research, ingenuity and broad therapeutic potentialities, all of which should increase patient outcomes, attract funding, and accelerate the development and access to successful treatments for Duchenne muscular dystrophy (DMD). Case in point, according to ClinicalTrials.gov, an extension of The National Institutes of Health (NIH), a US government organization tasked with performing and backing medical research, the count of registered clinical trials rose to 464,218, up from 399,496 in 2021, spanning all 50 US states and 221 countries. Furthermore, 142,700 trials (31% of the total) are registered in the United States and 248,310 trials (53% of the full tally) are registered outside the U.S. As a result, the growing number of clinical trials is set to guide the growth in the Duchenne muscular dystrophy (DMD) therapeutics market.
Which Sub-Segments Are Driving Growth Within The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
The duchenne muscular dystrophy (dmd) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies
What Future-Focused Trends Are Anticipated In The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
Leading businesses in the duchenne muscular dystrophy (DMD) therapeutics market are leveraging new technologies to improve the efficiency and availability of DMD treatments, thereby maintaining their market stance. For instance, Bit Bio Ltd., a synthetic biology firm based in the UK, in July 2023 introduced disease model products aimed at progressing DMD therapies. These disease models, named ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, are human skeletal myocytes with genetically designed deletions in the dystrophin protein producing gene. Bit. Bio’s reprogrammed models, derived from induced pluripotent stem cells (iPSCs), offer a reliable and expandable human cell source for research, overcomes challenges related to variability and primary cell sourcing. These models facilitate the development of DMD treatments by providing valuable insights into disease processes and potential treatments, potentially speeding up the efforts of researchers in finding effective DMD treatments.
Which Organizations Are At The Forefront Of The Duchenne Muscular Dystrophy (DMD) Therapeutics Market?
Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings PLC, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.
Access The Complete Report Here:
Which Region Dominates The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Today?
North America was the largest region in the DMD therapeutics market in 2024. The regions covered in duchenne muscular dystrophy (DMD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=12916&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
